奥西默替尼
医学
中止
T790米
内科学
肺癌
肿瘤科
肺炎
临床试验
酪氨酸激酶抑制剂
癌症
肺
表皮生长因子受体
埃罗替尼
吉非替尼
作者
Filippo de Marinis,Yi‐Long Wu,Gilberto de Castro,Gee Chen Chang,Yuh Min Chen,Byoung Chul Cho,Helano C. Freitas,Liyan Jiang,Sang We Kim,Claudio Martín,Giulio Metro,Mariano Provencio,Johan Vansteenkiste,David Vicente,Qing Zhou,Miguel Miranda,Nicolaas A. Bakker,James R. Rigas,Parneet Cheema
出处
期刊:Future Oncology
[Future Medicine]
日期:2019-09-01
卷期号:15 (26): 3003-3014
被引量:43
标识
DOI:10.2217/fon-2019-0324
摘要
Aim: Osimertinib is a third-generation, irreversible, oral EGFR tyrosine kinase inhibitor. We report real-world effectiveness and safety data. Patients & methods: EGFR T790M positive advanced non-small-cell lung cancer adults, who received ≥1 prior EGFR tyrosine kinase inhibitor, received osimertinib 80 mg daily. Primary effectiveness outcome: overall survival. Secondary effectiveness outcomes included: investigator-assessed clinical response, progression-free survival, time-to-treatment discontinuation. Results: At data cutoff, 3015 patients had enrolled: 57.1% had investigator-assessed response (95% CI: 55.2–58.9). Median progression-free survival: 11.1 months (95% CI: 11.0–12.0) and median time-to-treatment discontinuation: 13.5 months (95% CI: 12.6–13.9). Interstitial lung disease/pneumonitis-like events reported in 28 (1%) patients. Conclusion: Osimertinib demonstrated clinical effectiveness similar to efficacy observed in the clinical trial program with no new safety signals.
科研通智能强力驱动
Strongly Powered by AbleSci AI